SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001516551-23-000034
Filing Date
2023-03-27
Accepted
2023-03-27 16:09:11
Documents
12
Period of Report
2023-02-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A skye-20230214.htm   iXBRL 8-K/A 30098
  Complete submission text file 0001516551-23-000034.txt   148510

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20230214.xsd EX-101.SCH 1921
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20230214_lab.xml EX-101.LAB 22080
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20230214_pre.xml EX-101.PRE 11526
6 EXTRACTED XBRL INSTANCE DOCUMENT skye-20230214_htm.xml XML 3808
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-55136 | Film No.: 23764633
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences